Corcept Therapeutics reported that relacorilant, its oral selective glucocorticoid receptor antagonist, reduced risk of death by 35% in a Phase III ovarian cancer trial when added to chemotherapy. The company said the Rosella trial met its overall survival endpoint and earlier showed progression‑free survival benefits, positioning relacorilant for potential regulatory filings ahead of a mid‑year PDUFA window. Corcept highlighted the data as a pivotal efficacy signal for platinum‑resistant ovarian cancer and is preparing submissions and commercialization planning in parallel with regulatory interactions.